ArticleClinical drug investigation2026
Modeling the Budget Impact of Disease-Modifying Therapies in Infantile-Onset Spinal Muscular Atrophy.
Article in Clinical drug investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveNusinersen, onasemnogene abeparvovec-xioi, and risdiplam are disease-modifying therapies that have demonstrated clinical benefits for patients with spinal muscular atrophy. However, their high costs pose significant challenges for healthcare payers. This study evaluated the potential budget impact of these treatments compared with best supportive care from a US healthcare payer perspective.
methodsA budget impact analysis was conducted over a 5-year time horizon using a state-transition model to estimate direct healthcare costs associated with each disease-modifying therapy and best supportive care in a cohort of children with infantile-onset spinal muscular atrophy. A scenario analysis also assessed the budget impact over a lifetime horizon. Model inputs for transitions and costs were derived from clinical trials, observational registries, and administrative databases.
resultsCompared with best supportive care, the added 5-year per-patient budget impact was $2.18 million for onasemnogene abeparvovec-xioi, $1.51 million for nusinersen, and $1.17 million for risdiplam. When modeled over a lifetime horizon, the incremental per-patient budget impact versus best supportive care was $5.86 million for risdiplam, $3.16 million for onasemnogene abeparvovec-xioi, and $3.05 million for nusinersen.
conclusionsDisease-modifying therapies for the management of infantile-onset spinal muscular atrophy have a substantial budget impact on US healthcare payers, primarily driven by high drug acquisition costs. The impact (per year) becomes less pronounced when evaluated over a longer time horizon, with the largest lifetime budget impact observed for risdiplam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.